Metraipolis › archive › dc_b0847bfd8335
Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins — Europe PMC PMID:41066396
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41066396
- DOI
- 10.1371/journal.pone.0334013
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T11:21:32.809Z
- SHA-256 of the archived text
10caa9dcec6ef8161c7398e1dced99d1d97adf0fc554f000c204d06271966998- Stable URL of this page
https://metraipolis.com/documento/dc_b0847bfd8335
How to cite
Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins — Europe PMC PMID:41066396 — Europe PMC (en), https://europepmc.org/article/MED/41066396 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b0847bfd8335 (Metraipolis archive dc_b0847bfd8335, sha256 10caa9dcec6ef8161c7398e1dced99d1d97adf0fc554f000c204d06271966998)
BibTeX
@misc{dcb0847bfd8335,
title = {Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins — Europe PMC PMID:41066396},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41066396},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b0847bfd8335; sha256 10caa9dcec6ef8161c7398e1dced99d1d97adf0fc554f000c204d06271966998},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41066396. Agents can read the archived copy with the MCP tool read_document.